HCP

Patients & Caregivers

Listen to the Gifted Life episode with Brandi Zofkie, Episode 167: Lung Bioengineering

bg 1
EVLP. Where INNOVATION meets transplantation.

An introduction to ex vivo lung perfusion (EVLP): innovation designed to increase the pool of available donor lungs for transplantation.

about evlp

IMPORTANT SAFETY INFORMATION FOR XVIVO PERFUSION SYSTEM (XPS™) WITH STEEN SOLUTION™ PERFUSATE - P180014

Warnings and Precautions

General Warnings

The safety and effectiveness of the XPS™ System with STEEN Solution™ Perfusate device were not evaluated with ideal criteria donor lungs.

Risk for Contamination and Mechanical Trauma

The degree of organ manipulation required for airway and vascular cannulation carries the potential for contamination and mechanical trauma of the donor lungs. Even though not contraindicated, it is not recommended to use an organ with evident signs of mechanical trauma or major contamination.

Please see full Important Safety Information by clicking the button below

Viable solutions for challenging organs

For many patients suffering with end-stage lung disease, transplant is their only lifeline. Yet, the number of patients on the lung transplant wait list significantly exceeds the amount of available donor lungs.

What makes a placing donor lung challenging? EVLP aims to find new answers to this question and uncover more possibilities for more patients.

Organ Shortage Continues in the U.S

Annual Number of Patients on Waiting List, Transplants Received, and Living and Deceased Donors in the United States, 1991–2019

about evlp graphabout evlp graph legend
Data from optn.transplant.hrsa.gov and OPTN/SRTR Annual Report.

What is EVLP?

EVLP is a technique used to evaluate donor lungs outside of the human body. It has emerged as an essential tool for transplant physicians to increase the number of lungs available for transplantation.

For example, when marginal lungs do not meet standard direct-to-transplant criteria, they are often not used. With the help of EVLP, marginal lungs can now be monitored and clinically assessed to help transplant centers determine transplant suitability.

EVLP is innovation that gives lungs a second chance.

Image 1
Image 2
Image 3

The EVLP difference

further evaluation

further evaluation

Facilitates the use of donor lungs by providing further evaluation of organs.

OPPORTUNITY TO INCREASE conversion rate

OPPORTUNITY TO INCREASE conversion rate

Aims to increase the conversion rate of donor lungs that would otherwise have gone unused.

added time

added time

Can provide additional time in circumstances where procurement occurs without comprehensive evaluation.

FLEXIBILITY in recipient transplant timing

FLEXIBILITY in recipient transplant timing

Provides flexibility in recipient transplant timing when there is a need for prospective crossmatch and further recipient testing, donor instability, DCDs (Donation after Circulatory Death) or explant of native lungs.

Increased confidence

Increased confidence

Increases confidence in using lungs recovered by other teams, decreasing dry runs by transplant center explant teams so that they can successfully transplant more lungs.

backup modality

backup modality

Makes the assessment of additional lungs possible via access to EVLP as a backup modality.

“ [With EVLP] we have been able to utilize some lungs that otherwise would not have been used for transplant.”

Dr. Matthew Hartwig
Transplant Surgeon, Duke University

Interested in learning more? Browse our EVLP library below.

1

EX VIVO PERFUSION TECHNIQUES: STATE OF THE ART AND POTENTIAL APPLICATIONS

Marcelo Cypel, Arne Neyrinck and Tiago N. Machuca

2

EX VIVO LUNG PERFUSION: CURRENT ACHIEVEMENTS AND FUTURE DIRECTIONS

Nikhil K. Prasad, MB, ChB, Chetan Pasrija, MD, Tara Talaie, MD, Alexander S. Krupnick, MD, Yunge Zhao, MD, PhD, and Christine L. Lau, MD, MBA

3

A POTENTIAL SOLUTION TO THE SHORTAGE OF SOLID ORGANS FOR TRANSPLANTATION

Stephen P. Wall, MD, MSc, MAEd; Carolyn Plunkett, MA; Arthur Caplan, PhD

4

EXTENDED POST-EX VIVO LUNG PERFUSION COLD PRESERVATION PREDICTS PRIMARY GRAFT DYSFUNCTION AND MORTALITY: RESULTS FROM A MULTICENTRIC STUDY

Leiva-Juárez, Miguel M. et al.

5

LUNG TRANSPLANTATION AFTER EX VIVO LUNG PERFUSION EARLY OUTCOMES FROM A US NATIONAL REGISTRY

Oliver K. Jawitz, MD, MHS, Vignesh Raman, MD, MHS, David Becerra, MD, Julie Doberne, MD, PhD, Ashley Y. Choi, BA, Samantha E. Halpern, BA, Jacob A. Klapper, MD, and Matthew G. Hartwig, MD

6

EX-VIVO LUNG PERFUSION IN DONATION AFTER CIRCULATORY DEATH LUNG TRANSPLANTATION INCREASES DONOR UTILIZATION: ANALYSIS OF THE NOVEL EXTENSION TRIAL

B.A. Whitson, B. Shukrallah, M.S. Mulligan, J. D'Cunha, M. Daneshmand, T. Wozniak, Z. Kon, T. Machuca, M. Jessen, P. Sanchez, E. Cantu

Ready to start your journey with us?

Become an LBE partner
lbe logo
call us
Referral line: 1 (844) 367-3857

© 2024 Lung Bioengineering | All rights reserved. | www.lungbioengineering.com

US-LBE-0042

© 2024 Lung Bioengineering | All rights reserved. | www.lungbioengineering.com | US-LBE-0042